Figure S1

A

B

0 nM 1nM 5nM 25 nM 125 nM 625 nM 0

0.2

0.4

0.6

0.8

1

1.2

MCF7

INK 128

RAD001

GDG00941

Drug Concentration

Via

bil

ity

0 nM 1nM 5nM 25 nM 125 nM 625 nM 0

0.2

0.4

0.6

0.8

1

1.2

MCF7/HER2-18

INK 128

RAD001

GDG00941

Drug Concentration

Via

bil

ity

0 nM 1nM 5nM 25 nM 125 nM 625 nM 0

0.2

0.4

0.6

0.8

1

1.2

SKBR3

INK 128

RAD001

GDG00941

Drug Concentration

Via

bil

ity

C

Figure S2

MLN

0128

0 nM

5 nM

25 n

M

125

nM

0 nM

5 nM

25 n

M

125

nM

0 nM

5 nM

25 n

M

125

nM

SAHA 0 nM 625 nM 3125 nM

0

0.2

0.4

0.6

0.8

1

1.2

MCF7V

iabi

lity

 Antagonism Synergism

Additivity

SAHA(nM)

625 625 625 3125 3125 3125

MLN0128(nM)

5 25 125 5 25 125

CI 0.728 0.394 0.368 0.412 0.206 0.151

A

B

Figure S3

DMSO

MLN0128

TSA

MLN0128/TSA

Bright-field Annexin V PI merge

no tr

eatm

ent

pAKT S473

AKT

0 1000

0 25

TSA (nM)

INK128 (nM)

50

0 25 0 25

pAKT T308

Figure S4

SKBR3